BioCryst Pharmaceuticals announced that the Canadian Agency for Drugs and Technologies in Health, or CADTH, Canadian Drug Expert Committee, or CDEC, has issued a positive recommendation for Orladeyo to be reimbursed for the routine prevention of attacks of hereditary angioedema, or HAE, in adults and pediatric patients 12 years of age and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst presents new long-term, real-world data on ORLADEYO
- BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)